标题:Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack Secondary Analysis of a Randomized Clinical Trial
作者:Pan, Yuesong; Chen, Weiqi; Wang, Yilong; Li, Hao; Johnston, S. Claiborne; Simon, Tabassome; Zhao, Xingquan; Liu, Liping; Wang, David; 更多
通讯作者:Wang, YJ
作者机构:[Pan, Yuesong; Chen, Weiqi; Wang, Yilong; Li, Hao; Zhao, Xingquan; Liu, Liping; Meng, Xia; Wang, Yongjun; Li, Jianhua; Li, Juntao; Li, Guanglai; Chen, 更多
会议名称:11th World Stroke Congress
会议日期:OCT 20, 2018
来源:JAMA NEUROLOGY
出版年:2019
卷:76
期:5
页码:552-560
DOI:10.1001/jamaneurol.2018.4775
摘要:IMPORTANCE Genetic variants of ABCB1 may affect intestinal absorption of clopidogrel bisulfate. However, it is unclear whether ABCB1 polymorphisms are associated with clopidogrel efficacy for minor ischemic stroke or transient ischemic attack (TIA).; OBJECTIVES To investigate the association between ABCB1 polymorphisms and clopidogrel efficacy for minor stroke or TIA.; DESIGN, SETTING, AND PARTICIPANTS In this prespecified secondary analysis of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events (CHANCE) randomized clinical trial, 3010 patients with minor stroke or TIA at 73 sites in China with experience in conducting genetic studies were included from October 1, 2009, to July 30, 2012. The analysis was conducted on March 20, 2018. Four single-nucleotide polymorphisms (ABCB1-154T>C [rs4148727], ABCB13435C>T [rs1045642], CYP2C19*2 [681G>A, rs4244285], and CYP2C19*3 [636G>A, rs4986893]) were genotyped among 2836 patients treated with clopidogrel plus aspirin (n = 1414) or aspirin alone (n = 1422). The association of ABCB1 genetic variants (-154 TC/CC and 3435 CT/TT) with clopidogrel efficacy was evaluated in the context of CYP2C19 status, another gene associated with clopidogrel efficacy.; INTERVENTIONS Patients in the CHANCE trial were randomized to treatment with clopidogrel combined with aspirin or to aspirin alone.; MAIN OUTCOMES AND MEASURES Primary efficacy outcome was stroke recurrence after 3 months. The safety outcome was any bleeding risk after 3 months.; RESULTS Among 2836 patients, the median age was 61.8 years (interquartile range, 54.4-71.1 years) and 1887 patients (66.5%) were male. A total of 2146 (75.7%) patients were carriers of ABCB1-154TC/CC (570 [20.1%]) or 3435 CT/TT (1851 [65.3%]) genotype. Clopidogrel plus aspirin treatment was associated with reduced risk of new stroke in patients with ABCB1-154 TT and 3435 CC genotype (hazard ratio [HR], 0.43; 95% Cl, 0.26-0.71) but not in those with ABCB1 -154 TC/CC or 3435 CT/TT genotype (HR, 0.78; 95% CI, 0.60-1.03) compared with aspirin (P=.04 for interaction). A combined association of ABCB1 and CYP2C19 polymorphisms with new stroke was observed. The risk of bleeding for clopidogrel plus aspirin treatment was not associated with the ABCB1 genotypes (2.3% and 1.3% vs 1.9% and 2.2%; P=.25 for interaction in patients with or without ABCB1-154 TC/CC or 3435 CT/TT genotype); CONCLUSIONS AND RELEVANCE The ABCB1 polymorphism was associated with the reduced efficacy of clopidogrel plus aspirin treatment compared with aspirin among patients with minor ischemic stroke or TIA. Genetic polymorphism of ABCB1 should be considered when prescribing clopidogrel for these patients.
收录类别:CPCI-S;SCIE
WOS核心被引频次:1
资源类型:会议论文
TOP